Work

Beneficiaries who are Black or Latino/a are more likely than white beneficiaries to report difficulty with activities of daily living (ADLs) and other conditions that can negatively impact their health. Understanding the experiences of individuals reporting difficulty with ADLs across race and ethnicity can help policymakers develop strategies to address inequities. This databook, supported by the Robert Wood Johnson Foundation, conveys research findings on the racial and ethnic disparities among this population across social determinants of health, natural community supports, and health care experiences.

ATI Advisory in partnership with the Rosalynn Carter Institute for Caregivers (RCI) sought to explore the evidence and needs of dementia caregivers that might inform a Medicare model test related to dementia care. On July 31, 2023, the Center for Medicare and Medicaid Innovation (CMMI) released the Guiding an Improved Dementia Experience (GUIDE) Model that includes explicit support for caregivers and is set to launch in July 2024.

ATI Advisory in partnership with the Rosalynn Carter Institute for Caregivers (RCI) sought to explore the evidence and needs of dementia caregivers that might inform a Medicare model test related to dementia care. On July 31, 2023, the Center for Medicare and Medicaid Innovation (CMMI) released the Guiding an Improved Dementia Experience (GUIDE) Model that includes explicit support for caregivers and is set to launch in July 2024.

Since 2019, ATI Advisory and the Long-Term Quality Alliance, with support from The SCAN Foundation, have led national efforts to advance person-centered, non-medical supplemental benefits in Medicare Advantage.

The Centers for Medicare & Medicaid Services announced the first 10 drugs to be negotiated by Medicare. As CMS and pharmaceutical manufacturers prepare for negotiations, they will consider not only the effectiveness of these drugs, but also their financial performance and investment over the years. To create a public benchmark of these measures, ATI collected data from FDA labels, Evaluate Pharma and Omnium databases, the CMS spending dashboard, and proprietary data. For each drug, we present a summary of its time on the market, use in Medicare, clinical development activity and investment, global and U.S. sales, its position in the manufacturer’s portfolio, and deal history.

ATI Advisory is pleased to release these first resources as part of our State Resource Center. We will continue to release state resources reflecting the latest insights and novel strategies, tip sheets, and education on the ever-changing market and federal policy environment, and what it means for states.